BioNTech (NASDAQ:BNTX) Price Target Cut to $140.00 by Analysts at Wells Fargo & Company

BioNTech (NASDAQ:BNTX) had its price target cut by Wells Fargo & Company from $150.00 to $140.00 in a report issued on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

BNTX has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Wednesday, April 8th. Leerink Partners lowered shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price target for the company. in a report on Monday, February 2nd. Raymond James Financial reissued an “outperform” rating on shares of BioNTech in a report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of BioNTech in a report on Tuesday, March 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $130.00 price objective on shares of BioNTech in a research report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $131.60.

BioNTech Price Performance

Shares of BNTX stock opened at $95.26 on Wednesday. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The firm has a market capitalization of $24.09 billion, a price-to-earnings ratio of -16.20 and a beta of 1.36. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $96.94 and a 200-day moving average of $100.99.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.33%. The firm had revenue of $1.06 billion during the quarter. On average, equities research analysts forecast that BioNTech will post -4.55 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On BioNTech

Several institutional investors have recently added to or reduced their stakes in BNTX. Royal Bank of Canada lifted its position in BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares in the last quarter. NewEdge Advisors LLC bought a new stake in BioNTech during the 1st quarter worth about $167,000. Russell Investments Group Ltd. lifted its position in BioNTech by 368,800.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,067 shares of the company’s stock worth $1,178,000 after buying an additional 11,064 shares in the last quarter. Natixis bought a new stake in BioNTech during the 2nd quarter worth about $985,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in BioNTech by 2.9% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 492,045 shares of the company’s stock worth $52,416,000 after buying an additional 13,788 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Company will buy back up to $1 billion of shares, supporting capital return and offsetting some negative sentiment from weaker sales. BioNTech to close sites in Germany, Singapore affecting 1,860 staff
• Positive Sentiment: Q1 EPS beat: reported ($2.26) vs consensus ($2.52) — the EPS beat shows some operating leverage despite collapsing vaccine revenue. BioNTech Q1 press release
• Positive Sentiment: Wells Fargo lowered its price target from $150 to $140 but kept an “overweight” stance, signaling some analyst confidence in medium‑term upside despite nearer‑term headwinds. Benzinga
• Neutral Sentiment: German government says national vaccine supply remains secure despite BioNTech production loss — reduces systemic risk from the production issue but does not change demand trends. Germany says vaccine supply secure despite BioNTech production loss
• Neutral Sentiment: Company provided a corporate update and slide deck with guidance; FY2026 revenue range ($2.3B–$2.7B) roughly brackets street estimates, leaving investors focused on execution vs. guidance. GlobeNewswire press release
• Neutral Sentiment: Full Q1 earnings call transcript is available for detail on product revenue mix, pipeline timing and restructuring plans (useful for assessing recovery scenarios). Earnings call transcript
• Negative Sentiment: Vaccine sales plunged: Q1 revenue $136.6M missed estimates (~$207M) and revenue fell ~35% YoY — core COVID product demand has declined materially. MarketBeat earnings summary
• Negative Sentiment: Major restructuring: BioNTech plans to cut roughly a quarter of its workforce and close sites in Germany and Singapore (about 1,860 roles affected) as it shrinks manufacturing footprint post‑pandemic — signals slower top‑line outlook and near‑term execution risk. WSJ: BioNTech to close sites, cut workforce
• Negative Sentiment: Leadership turnover tied to the shake‑up (co‑founders departing) adds governance/continuity concerns during the transition. Reuters on site closures and leadership

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.